Medigen Vaccine Biologics Corp (高端疫苗) yesterday reported positive results from an interim analysis of phase 2 trials for its COVID-19 vaccine, saying that the vaccine demonstrated high seroconversion rates and geometric mean titer (GMT) figures.
A seroconversion rate is the percentage of participants in a trial displaying virus-specific immune memory after being given a vaccine, while the GMT measures the level of neutralizing antibody response, Medigen said.
The experimental vaccine has a seroconversion rate of 99.8 percent and its GMT was 662 among the participants aged 20 to 89, while the gauges rose to 99.9 percent and 733 respectively in participants aged 20 to 64, the company said.
Photo: Screen grab from the Internet
No participants have shown severe adverse reactions, it said.
Only 0.7 percent of participants who were given experimental vaccines had a fever, compared with 0.4 percent in those who received a placebo, while among those who received the vaccine 27.6 percent had muscle soreness and 36 percent felt tired, compared with 16.6 percent and 29.7 percent respectively for those who were given a placebo, it said.
“It would be the regulator that decides if our experimental vaccine has good efficacy, but I personally found the results — the seroconversion rates and the GMT figures — optimistic,” Medigen chief executive officer Charles Chen (陳燦堅) said.
“And it is very safe,” Chen added.
The company will apply to the Food and Drug Administration for emergency use authorization as soon as possible, he said.
However, asked which COVID-19 vaccine developed outside Taiwan that has been granted emergency use authorization Medigen’s experimental vaccine might be compared to, the company said it has not reached a conclusion.
“An estimate needs to be done scientifically. We can conduct an immune-bridging study to compare the antibody levels in people who are given different COVID-19 vaccines, and the WHO is also trying to establish common standards for COVID-19 vaccines,” Medigen head of development Lien Chia-en (連加恩) said.
For example, Medigen’s clinical trial result of a GMT of 662 could be converted into international units (IU) and foreign vaccine developers could do likewise to enable international comparison, Lien said.
“However, this would take some time and other companies have not disclosed their data in IU yet,” he said.
Amid discussions over whether locally developed COVID-19 vaccines would be better than foreign vaccines, Chen and Medigen spokesman Leo Lee (李思賢) said that they are confident in their product and they and their families would get Medigen’s vaccine.
Medigen is to conduct phase 3 trials for its vaccine to earn approval from foreign regulators and it aims to conduct the tests in Europe, Chen said, adding that the UK recently allowed a French company to conduct phase 3 human testing there.
It costs about US$10,000 per participant in phase 3 trials, so the costs would be enormous if Medigen recruited 30,000 participants, Chen said.
Beijing’s continued provocations in the Taiwan Strait reveal its intention to unilaterally change the “status quo” in the area, the US Department of State said on Saturday, calling for a peaceful resolution to cross-strait issues. The Coast Guard Administration (CGA) reported that four China Coast Guard patrol vessels entered restricted and prohibited waters near Kinmen County on Friday and again on Saturday. A State Department spokesperson said that Washington was aware of the incidents, and urged all parties to exercise restraint and refrain from unilaterally changing the “status quo.” “Maintaining peace and stability across the Taiwan Strait is in line with our [the
EXTENDED RANGE: Hsiung Sheng missiles, 100 of which might be deployed by the end of the year, could reach Chinese command posts and airport runways, a source said A NT$16.9 billion (US$534.93 million) project to upgrade the military’s missile defense systems would be completed this year, allowing the deployment of at least 100 long-range Hsiung Sheng missiles and providing more deterrence against China, military sources said on Saturday. Hsiung Sheng missiles are an extended-range version of the Hsiung Feng IIE (HF-2E) surface-to-surface cruise missile, and are believed to have a range of up to 1,200km, which would allow them to hit targets well inside China. They went into mass production in 2022, the sources said. The project is part of a special budget for the Ministry of National Defense aimed at
READY TO WORK: Taiwan is eager to cooperate and is hopeful that like-minded states will continue to advocate for its inclusion in regional organizations, Lai said Maintaining the “status quo” in the Taiwan Strait, and peace and stability in the Indo-Pacific region must be a top priority, president-elect William Lai (賴清德) said yesterday after meeting with a delegation of US academics. Leaders of the G7, US President Joe Biden and other international heads of state have voiced concerns about the situation in the Strait, as stability in the region is necessary for a safe, peaceful and prosperous world, Lai said. The vice president, who is to be inaugurated in May, welcomed the delegation and thanked them for their support for Taiwan and issues concerning the Strait. The international community
COOPERATION: Two crewmembers from a Chinese fishing boat that sank off Kinmen were rescued, two were found dead and another two were still missing at press time The Coast Guard Administration (CGA) was yesterday working with Chinese rescuers to find two missing crewmembers from a Chinese fishing boat that sank southwest of Kinmen County yesterday, killing two crew. The joint operation managed to rescue two of the boat’s six crewmembers, but two were already dead when they were pulled from the water, the agency said in a statement. Rescuers are still searching for two others from the Min Long Yu 61222, a boat registered in China’s Fujian Province that capsized and sank 1.03 nautical miles (1.9km) southwest of Dongding Island (東碇), it added. CGA Director-General Chou Mei-wu (周美伍) told a